ZIOPHARM Oncology, Inc is a biotechnology business based in the US. ZIOPHARM Oncology shares (ZIOP) are listed on the NASDAQ and all prices are listed in US Dollars. ZIOPHARM Oncology employs 103 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Social investors
| Latest market close | $3.03 |
|---|---|
| 52-week range | $2.06 - $5.95 |
| 50-day moving average | $2.57 |
| 200-day moving average | $3.48 |
| Wall St. target price | $5.08 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.58 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.03 from 2021-05-26
| 1 week (2021-07-25) | N/A |
|---|---|
| 1 month (2021-07-02) | 14.77% |
| 3 months (2021-05-05) | 3.03 |
| 6 months (2021-02-01) | N/A |
| 1 year (2020-08-01) | N/A |
|---|---|
| 2 years (2019-08-01) | N/A |
| 3 years (2018-08-01) | N/A |
| 5 years (2016-08-01) | N/A |
| Gross profit TTM | $-52,696,000 |
|---|---|
| Return on assets TTM | -31.62% |
| Return on equity TTM | -58.21% |
| Profit margin | 0% |
| Book value | $0.49 |
| Market capitalisation | $484.9 million |
TTM: trailing 12 months
There are currently 35.7 million ZIOPHARM Oncology shares held short by investors – that's known as ZIOPHARM Oncology's "short interest". This figure is 1.3% up from 35.2 million last month.
There are a few different ways that this level of interest in shorting ZIOPHARM Oncology shares can be evaluated.
ZIOPHARM Oncology's "short interest ratio" (SIR) is the quantity of ZIOPHARM Oncology shares currently shorted divided by the average quantity of ZIOPHARM Oncology shares traded daily (recently around 1.7 million). ZIOPHARM Oncology's SIR currently stands at 20.43. In other words for every 100,000 ZIOPHARM Oncology shares traded daily on the market, roughly 20430 shares are currently held short.
However ZIOPHARM Oncology's short interest can also be evaluated against the total number of ZIOPHARM Oncology shares, or, against the total number of tradable ZIOPHARM Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ZIOPHARM Oncology's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 ZIOPHARM Oncology shares in existence, roughly 170 shares are currently held short) or 0.2002% of the tradable shares (for every 100,000 tradable ZIOPHARM Oncology shares, roughly 200 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against ZIOPHARM Oncology.
Find out more about how you can short ZIOPHARM Oncology stock.
We're not expecting ZIOPHARM Oncology to pay a dividend over the next 12 months.
ZIOPHARM Oncology's shares were split on a 1:40 basis on 23 August 2005. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ZIOPHARM Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for ZIOPHARM Oncology shares which in turn could have impacted ZIOPHARM Oncology's share price.
Over the last 12 months, ZIOPHARM Oncology's shares have ranged in value from as little as $2.06 up to $5.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ZIOPHARM Oncology's is 2.0098. This would suggest that ZIOPHARM Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ZIOPHARM Oncology, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc. ; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc.
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
